Next Article in Journal
An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
Previous Article in Journal
Circulating Cancer Biomarkers
 
 
Article

Article Versions Notes

Cancers 2021, 13(4), 803; https://doi.org/10.3390/cancers13040803
Action Date Notes Link
article xml file uploaded 15 February 2021 07:20 CET Original file -
article xml uploaded. 15 February 2021 07:20 CET Update -
article pdf uploaded. 15 February 2021 07:20 CET Version of Record https://www.mdpi.com/2072-6694/13/4/803/pdf-vor
article html file updated 15 February 2021 07:22 CET Original file -
article xml file uploaded 15 February 2021 13:31 CET Update -
article xml uploaded. 15 February 2021 13:31 CET Update -
article pdf uploaded. 15 February 2021 13:31 CET Updated version of record https://www.mdpi.com/2072-6694/13/4/803/pdf-vor
article html file updated 15 February 2021 13:32 CET Update -
article xml file uploaded 17 February 2021 02:07 CET Update -
article xml uploaded. 17 February 2021 02:07 CET Update https://www.mdpi.com/2072-6694/13/4/803/xml
article pdf uploaded. 17 February 2021 02:07 CET Updated version of record https://www.mdpi.com/2072-6694/13/4/803/pdf
article html file updated 17 February 2021 02:09 CET Update -
article html file updated 25 July 2022 03:32 CEST Update https://www.mdpi.com/2072-6694/13/4/803/html
Back to TopTop